Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
Home Print this page Email this page
Users Online:778
ORIGINAL ARTICLE
Year : 2019  |  Volume : 7  |  Issue : 2  |  Page : 68-73

Role of thiamine supplementation in the treatment of patients with heart failure: A double-blind randomized controlled trial


1 Department of Cardiology, SKIMS, Soura, Jammu and Kashmir, India
2 Department of Cardiology, GMC, Srinagar, Jammu and Kashmir, India

Correspondence Address:
Dr. Aamir Rashid
House No. 8, LD Colony Rawalpora, Srinagar - 190 005, Jammu and Kashmir
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/heartindia.heartindia_7_19

Rights and Permissions

Introduction: The role of thiamine supplementation in heart failure (HF) patients has shown conflicting results and has not been adequately studied. Aims and Objectives: The aim and objective were to determine whether thiamine supplementation will provide clinical, biochemical, and echocardiographic benefit in congestive HF patients. Materials and Methods: In this single-center, double-blind, prospective randomized controlled trial, HF patients with varied etiology were included. Patients were randomly allocated to 1 week of inpatient double-blind intravenous therapy with either placebo or thiamine. Parameters studied included clinical, Echo left ventricular ejection fraction (LVEF), and thiamine pyrophosphate effect (TPPE) levels before/after treatment. After completion of 1-week treatment, all patients were given oral thiamine and evaluated at the outpatient clinic after 6 weeks. Results: A total of fifty patients were studied. There was no difference at baseline in mean age (61.4 ± 7.1 vs. 62.4 ± 8.0 years), sex (males 52% vs. 56%), etiology (idiopathic dilated cardiomyopathy 68% vs. 60%, ischemic heart disease 20% vs. 24%), clinical parameters, TPPE levels (16.4 ± 5.2 vs. 16.2 ± 6.5%), and LVEF (28.1% ± 6.7% vs. 28.3% ± 6.6%) in thiamine as compared to placebo group. After 1 week of treatment, there was significant improvement in systolic blood pressure (119.2 ± 18.3 vs. 106.1 ± 18.9 mmHgP < 0.001), diastolic blood pressure (77.4 ± 8.3 vs. 68.2 ± 9.7 mm HgP < 0.001), heart rate (67.0 ± 8.4 vs. 81.9 ± 10.7P < 0.001), weight (66.2 ± 9.5 vs. 71.2 ± 8.2 kgP < 0.001), 3rd-day urine output (1286.0 ± 505.7 ml vs. 750.0 ± 237.2 ml [P < 0.001]), New York Heart Association class (1.6 ± 0.5 vs. 2.1 ± 0.4P < 0.001), LVEF percentage change (7.0 ± 5.2 vs. 0.7% ± 4.7%P < 0.001), and TPPE levels (6.8% ± 1.5% vs. 16.0% ± 6.7%P < 0.001) in thiamine compared with placebo group. Conclusions: Thiamine supplementation significantly improved clinical and echocardiographic parameters. Thiamine supplementation is cost-effective, is benign, and is easily available with significant clinical benefits.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed540    
    Printed46    
    Emailed0    
    PDF Downloaded84    
    Comments [Add]    

Recommend this journal